Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P574. Change of quality of life during one year infliximab therapy course in children with inflammatory bowel disease
Authors:

D. Szabo1, G. Kokonyei2, A. Arato1, A. Dezsofi1, K. Molnar1, K.E. Muller1, G. Veres1, 1Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary, 2Eötvös Lóránd University, Institute of Psychology, Budapest, Hungary

P574

The efficacy of azathioprine and tumour necrosis factor antagonists in preventing Crohn's Disease recurrence after ileal resection: a tertiary center real-life experience

Authors:

M. Allocca*1, G. Fiorino1, M. Alfieri1, P. Turri1, M. Delliponti1, D. Gilardi1, I. Bravatà2, M. Sacchi3, A. Spinelli3, A. Repici2, S. Danese1

1Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy, 2Humanitas Research Hospital, Endoscopy Unit, Gastroenterology, Rozzano, Milan, Italy, 3Humanitas Research Hospital, IBD Surgery, Colo-rectal Surgery, Rozzano, Milan, Italy

P575.

A new tool for the surveillance of Crohn's perianal fistulae

Authors:

N.A. Yassin1, P.F. Lung1, A. Askari1, P.E. Edwards2, R.K.S. Phillips1, A. Gupta1, A.L. Hart1, 1St Mark's Hospital, and Academic Institute, London, United Kingdom, 2Imperial College London, Computer Science, London, United Kingdom

P575. Caseload and impact of the Leeds Combined Rheumatology and Gastroenterology Clinic
Authors:

T. Shuto1, R. Thomas1, S. Bingham1, L. Coates1, P. Emery1, H. Marzo-Ortega1, P.J. Hamlin2, 1University of Leeds, Rheumatic and Musculoskeletal disease, Leeds, United Kingdom, 2Leeds Teaching Hospital, Gastroenterology, Leeds, United Kingdom

P575

The use of mesenchymal stromal cells in order to achieve deep (biological) remission of Ulcerative Colitis

Authors:

O. Knyazev1, A. Kagramanova*1, A. Churikova1, A. Konoplyannikov2, S. Khomeriki3, A. Parfenov1, I. Ruchkina1

1Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation, 3Moscow Clinical Research Center, Department of Pathology, Moscow, Russian Federation

P576.

A nurse-led one-hour infusion protocol of infliximab is safe and improves infusion service efficiency

Authors:

R. D'Incà, A. Lupi, A. Buda, A. Favarin, M. Martinato, G.C. Sturniolo, V. Zanotto, Padua, Surgical, Gastroenterological and Oncological Sciences, Padua, Italy

P576. Calcium intake in patients with IBD
Authors:

P. Vernia1, P. Loizos1, I. Di Giuseppantonio1, B. Amore1, A. Chiappini1, S. Cannizzaro1, 1Sapienza Univerity of Rome, Medicina Interna e Specialità Mediche, Rome, Italy

P576

Therapeutic effects of mouse bone marrow-derived clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease

Authors:

K.B. Hahm*

CHA University, Gastroenterology, Seongnam, Korea, Republic of

P577.

Adverse effects of azathioprine in patients with inflammatory bowel disease (IBD)

Authors:

P. Ramirez de la Piscina, S. Estrada, I. Duca, K. Spicakova, I. Ganchegui, M.d.R. Calderón, A. Campos, M. Salvador, E. Delgado, J.M. López Barbarin, F. Garcia Campos, HUA Txagorritxu, Digestive, Vitoria-Álava, Spain

P577. Cost-effectiveness of episodic or maintenance infliximab versus standard treatment in an incidence cohort of Crohn's disease patients with 10-years follow-up
Authors:

S. Odes1, D. Greenberg2, H. Vardi3, M. Friger3, R. Stockbrugger4, P. Munkholm5, 1Soroka Medical Center and Ben Gurion University of the Negev, Gastorenterology and Hepatology, Beer Sheva, Israel, 2Ben Gurion University of the Negev, Health Systems Management, Beer Sheva, Israel, 3Ben Gurion University of the Negev, Epidemiology, Beer Sheva, Israel, 4Maastricht University Hospital, Gastroenterology and Hepatology, Maastricht, Netherlands, 5University of Copenhagen and Herlev Hospital, Gastroenterology, Copenhagen, Denmark

P577

Chemoprevention by mesalamine for colorectal cancer in UC-patients: a meta-analysis

Authors:

F. van Geest*, S. Koene, T. Kalisvaart, D. Dieleman, D. van Kalkeren, M. Peppelenbosch

Erasmus MC, Gastroenterology, Rotterdam, Netherlands

P578.

Adalimumab as first-line anti-TNF treatment in pediatric Crohn's disease

Authors:

J. Martín-de-Carpi1, V.M. Navas-Lopez2, M. Navalón-Rubio3, E. Llerena-Santa-Cruz1, D. Gil-Ortega3, V. Varea-Calderón1, C. Sierra-Salinas2, 1Hospital Sant Joan de Deu, Pediatric Gastroenterology and Nutrition Unit, Barcelona, Spain, 2Hospital Materno Infantil, Pediatric Gastroenterology and Nutrition Unit, Malaga, Spain, 3Hospital Virgen de la Arrixaca, Pediatric Gastroenterology and Nutrition, Murcia, Spain

P578. C-reactive protein levels at first month of adalimumab treatment as predictive of nonresponse in Crohn's disease patients
Authors:

E. Rodrigues-Pinto1, F. Magro1, F. Vilas-Boas1, J. Santos-Antunes1, A. Nunes1, S. Lopes1, C. Dias2, G. Macedo1, 1Centro Hospitalar São João, Faculdade Medicina Universidade Porto, Gastroenterology department, Porto, Portugal, 2Faculdade Medicina Universidade Porto, Health Decision and Information Science Department, Porto, Portugal

P578

Assessment of satisfaction with healthcare in patients with inflammatory bowel disease: An Online Korean Association for the Study of Intestinal Disease (KASID) Survey

Authors:

Y.S. Kim1, S.A. Jung*2, K.M. Lee3, S.J. Park4, T.O. Kim5, C.-H. Choi6, H.G. Kim7, W. Moon8, C.M. Moon9, H.K. Song2, S.-Y. Na10, S.-K. Yang11

1Seoul National University Hospital Healthcare System Gangnam center, Internal Medicine, Seoul, South Korea, 2Ewha University school of Medicine, Internal Medicine, Seoul, South Korea, 3The Catholic University College of Medicine, Internal Medicine, Seoul, South Korea, 4Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 5Haeundae Paik Hospital, Inje University College of Medicine, Internal Medicine, Seoul, South Korea, 6Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea, 7Soonchunhyang University College of Medicine, Internal Medicine, Seoul, South Korea, 8Kosin University College of Medicine, Internal Medicine, Seoul, South Korea, 9Ewha University school of Medicine, Internal Medicine, Seoul, Korea, Republic of, 10Jeju National University School of Medicine, Internal Medicine, Seoul, South Korea, 11Ulsan University College of Medicine, Internal Medicine, Seoul, South Korea

P579.

A cost of care model for inflammatory bowel disease

Authors:

N. Ghosh1, S. Leonard2, G. Miles2, P. Premchand1, 1Barking, Havering and Redbridge University Hospitals NHS Trust, Queen's Hospital, Romford, United Kingdom, 2Costello Medical Consulting, Publications, Cambridge, United Kingdom

P579. Bowel damage after biological therapy assessed by Sonographic Lesion Index for Crohn's disease
Authors:

F. Zorzi1, S. Zuzzi2, E. Stasi1, G. Bevivino1, C. Petruzziello1, L. Biancone1, C. Rossi2, F. Pallone1, E. Calabrese1, 1University of Rome Tor Vergata, GI Unit, Medicine, Rome, Italy, 2University of Rome Tor Vergata, Centro Interdipartimentale di Biostatistica e Bioinformatica, Rome, Italy

P579

Hematologic Malignancies Among 1740 Inflammatory Bowel Disease Patients: Long term follow up Data from a Tertiary Center

Authors:

A. Salihoglu1, N. Serin2, N. Esatoglu2, H. Yilmaz2, Y. Sengul2, I. Hatemi3, Y. Erzin3, A.F. Celik*3

1Istanbul University Cerrahpasa Medical Faculty, Hematology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey, 3Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey

P580.

A comparison of the pharmacokinetics of IMA-638, an anti-IL-13 monoclonal antibody, among healthy volunteers, subjects with asthma and ulcerative colitis patients

Authors:

W. Reinisch1, F. Hua2, J. Panes3, K. Page2, G.M. Comer2, F. Cataldi2, 1Medical University of Vienna, Internal Medicine/Gastroenterology, Vienna, Austria, 2Pfizer Inc., Gastroenterology, Cambridge, United States, 3Hospital Clinic I Provincial, Department of Inflammatory Disease, Barcelona, Spain

P580. Biologic therapy in pregnancy and inflammatory bowel disease: a prospective 7 year study: clinical outcome
Authors:

F. Habal1, 1University Health Network, Medicine, Toronto, Ontario, Canada

P580

Allogeneic hematopoetic stem cell transplantation to treat refractory Inflammatory Bowel Disease in an X-CGD carrier with non-random X-inactivation

Authors:

F. Hauck1, S. Koletzko*2, P. Bufler2, A. Klenk1, I. Schmid1, C. Klein1, M.H. Albert1

1Dr. von Hauner Children's Hospital, Ludwig Maximilians University , Pediatric Hematology/Oncology/Immunology/Stem Cell Transplantation,, Munich, Germany, 2Dr. von Hauner Children's Hospital, Ludwig Maximilians University , Pediatric Gastroenterology/Hepatology, Munich, Germany